Objective: Respiratory distress syndrome (RDS), requiring mechanical ventilation and exogenous surfactant treatment, and patent ductus arteriosus (PDA), are common co-morbidities in very premature infants. The effects of intra-tracheal surfactant administration on the cardiovascular and pulmonary systems in very premature infants with RDS and PDAs are not well characterized. We evaluated the effects of poractant alfa and beractant, surfactants with different rapidity of onset and duration of action, in very premature infants with RDS. To assess whether there were differences in PDA hemodynamics in very premature infants with RDS treated with poractant alfa and beractant during the first week of life and to assess whether poractant alfa or beractant had a direct effect on PDAs and PDA hemodynamics following the second dose of surfactant.
Introduction
Respiratory distress syndrome (RDS), requiring mechanical ventilation and exogenous surfactant treatment, and patent ductus arteriosus (PDA) are common co-morbidities in very premature infants. RDS requiring mechanical ventilation is treated with intratracheal surfactant. 1 The combined hemodynamic and pulmonary effects of surfactant administration on PDA hemodynamics in this population are not well characterized. Intratracheal surfactant may have direct and indirect hemodynamic effects. 2 Exogenous surfactant therapy, for example, may increase shunting across PDAs following rapid decreases in pulmonary vascular resistance. 3 Previous studies comparing these surfactant therapies have shown a higher 4 and lower 5 frequency of PDAs in infants treated with poractant alfa compared with those treated with beractant. We evaluated the hemodynamic effects of beractant (Survanta, Ross Product Division, Abbott Laboratories) and poractant alpha (Curosurf, Dey LP, Napa, CA, USA and Chiesi Farmaceutici Spa, Parma, Italy), the two most commonly used modified animalderived surfactants in the United States, in premature infants <30 weeks gestational age at birth with RDS. The goal of this paper was to describe PDA patency and hemodynamic differences in very premature infants with moderate to severe RDS treated with these two animal-derived surfactants. We were interested in both the potential direct and indirect effects of these surfactants on PDAs.
Respiratory support data for this study population were presented in a companion publication. 6 
Methods

Study design
A multi-site 1:1 randomized clinical trial comparing poractant alfa (2.5 ml kg -1 for initial dose and 1.25 ml kg -1 subsequent doses) to beractant (4 ml kg -1 for initial and subsequent doses) among very premature, in-born infants <30 weeks gestation was conducted at Boston Medical Center and Caritas St Elizabeth Medical Center, minimizing the variability in initial management of the patients enrolled. Institutional Review Board approval was obtained from each institution. The study was registered NCT00767039. Informed consent was obtained before delivery. Between January 2005 and May 2008, 52 infants with RDS were enrolled and randomized to receive either poractant alfa or beractant for the initial and subsequent doses. Early death occurred in two patients in the beractant group, before a significant PDA could manifest, and these patients were eliminated from analysis for this portion of the study. Entry criteria were in-born premature infants with gestational age <30 week, birth weight >500 g, RDS requiring mechanical ventilation with mean airway pressure X6 cm H 2 O and FiO 2 >30% before 8 h of life. Intratracheal surfactant was administered in two aliquots in left and right lateral positions, whereas the baby was supported on a volume cycle ventilator (Drager, Evita) with a tidal volume of 5 ml kg -1 , rate 35 breaths per min, inspiratory time 0.35 s and FiO 2 as need to maintain saturation 85 to 92%. Surfactant was administered as soon after birth as the diagnosis of RDS requiring intubation was made (within 6 h of birth). The first dose of beractant administration was at 24±17 min and the first dose of poractant alfa at 35 ± 54 min. The endotracheal tube was not suctioned for 1 h following surfactant instillation, unless clinically indicated. Early surfactant administration did not eliminate the need for respiratory support before 72 h in any of the infants included in this study.
Echocardiograms were obtained at 2 to 7 days of life, before institution of medical treatment of PDAs, to assess ductal patency and hemodynamics in the two groups. As this was the time when most PDAs are recognized, many of these echocardiograms were obtained for clinical indications (heart murmur, persistent mechanical ventilation or on CPAP with respiratory deterioration, increased apnea, hypotension or wide pulse pressure, etc.). Asymptomatic patients had echocardiograms at the convenience of the echocardiography technician within the specified time. Only patients with symptomatic PDAs that were hemodynamically significant by echocardiography were treated as clinically indicated (medically or surgically). Medical treatment used standard indomethacin dosing. 7 Subsequent echocardiograms were obtained as clinically indicated. Echocardiographical assessment included PDA size, right ventricular systolic pressure (RVP) derived from Doppler interrogation of Tricuspid regurgitant jet or PDA gradient, LA/Ao ratio, and systemic arterial blood pressure. Hemodynamically significant PDAs in patients on persistent respiratory support (ventilator or CPAP) were defined as having at least two of the following criteria: PDA>1.5 mm, diastolic retrograde flow in the descending aorta and/or left atrial enlargement with a left atrium to aortic root diameter ratio >1.4. Infants with significant congenital heart disease, multiple congenital anomalies or moribund infants anticipated to expire within the first 3 days of life were eliminated from the study. Echocardiograms were also obtained in a subset of 16 infants immediately before and 20 to 30 min after administration of the second dose of surfactant, to assess the direct effect of these surfactants on PDA hemodynamics. The differential effects of these surfactants on regional cerebral blood flow were previously reported. 8 If a PDA was hemodynamically significant or became significant at a later time, the infants were treated with indomethacin, unless there were medical contraindications (clinical diagnosis of necrotizing enterocolitis, thrombocytopenia <100 000, or impaired renal function with a creatinine >1.6 or BUN>35). We recorded when the infant was treated with indomethacin, the number of 3 dose courses administered and if surgical ligation was necessary.
Data analysis
Data were presented as mean±s.d. A student's t-test for continuous or w 2 for discrete variables, was used to determine statistical significance between the two groups for demographical (GA, gender, race, birth weight, antenatal betamethasone administration and SNAP II score), hemodynamic and treatment data. Apgar scores are presented as median (25 and 75 percentile), and compared using a Mann-Whitney rank sum test. The study was not designed to evaluate the long-term morbidities. The respiratory data were collected with corresponding hemodynamic data, to evaluate the effect of the two surfactant preparations on PDAs and PDA hemodynamics. Data analysis for this paper was generated using SAS software, Version 9.13 of the SAS System for Windows. Copyright 2004 SAS Institute SAS and all other SAS Institute product or service names are registered trademarks or trademarks of SAS Institutes, Cary, NC, USA.
Results
A total of 52 subjects were enrolled, 25 patients randomized to poractant alfa and 27 to beractant therapy group. Two patients in the beractant group died in the first week of life, before they would (Table 2) . PDA ligations were required in 4 of 25 (16%) of the poractant alfa and 7 of 25 (28%, P ¼ 0.311) of infants treated with beractant. Infants in the poractant alfa group tended to be treated earlier (3.4±2.5 days), than infants treated with beractant (5.1 ± 4.9 days, P ¼ 0.038).
The differences in PDA treatment between groups was associated with differences in the respiratory status that allowed early extubation (Figure 1 ) of more infants in the poractant alfa group (13 of 25, 52% at 48 h and 15 of 25, 60% at 72 h), than in the beractant group (6 of 25, 24% at 48 h, P ¼ 0.044, and 8 of 25, 32% at 72 h, P ¼ 0.049).
To determine whether there were early hemodynamic differences in the infants treated with poractant alfa and beractant, we prospectively performed echocardiographic evaluations of the infants at 2 to 7 days of life, before initiation of therapy for significant PDAs (Table 3 ). There were 25 infants in the poractant alfa and 25 in the beractant group that had echocardiographic studies in the first week. In the first week of life, PDAs (any size) were present in 15 of 25 (60%) of infants treated with poractant alfa and 14 of 25 (56%, P ¼ 0.562) infants treated with beractant. PDAs >1.5 mm were present in 12 of 25 (48%) of the poractant alfa group, with a mean PDA diameter of 2.4 ± 1.1 mm, and 10 of 25 (40%, P ¼ 0.573), with a mean diameter of 2.5 ± 0.6 mm (P ¼ 0.698), of the beractant treated infants. During the first week of life, RVP/Systolic Arterial Blood Pressure (SAP) was slightly lower in the poractant alfa (64±20%) than in the beractant group (78 ± 26%, P ¼ 0.048). Of the infants with any PDA in the first week of life, 8 of 15 (53%) of the infants in the poractant alfa and 14 of 14 (100%, P ¼ 0.0039) of the infants in the beractant group were treated with indomethacin or surgical ligation for significant PDAs during their NICU hospitalization. In addition, 5 infants in the beractant group developed hemodynamically significant PDAs after the first week. Poractant alfa treated infants required less respiratory support in the first 3 days of life than those treated with Figure 1 The number of patients extubated at 24, 48 and 72 h in the poractant alfa (solid bars) and beractant groups (clear bars) are shown. More infants in the poractant alfa group were extubated at 48 and 72 h (*P<0.05). (6) . Thus, there was a difference in the PDA management and hemodynamics in infants treated with poractant alfa, compared with beractant that was associated with improvement in respiratory status.
Patent ductus arteriosus hemodynamics
To determine whether there was a direct hemodynamic effect of surfactant on PDAs, we assessed PDA hemodynamics before (5 min baseline) and 20 to 30 min after the second dose of poractant alfa and beractant administration in 16 infants with RDS and PDAs ( Table 4) . The second or third dose of surfactant was administered for a mean airway pressure X6 cm H 2 O and FiO 2 >30%. A portion of these data were previously reported. 8 In the poractant alfa and beractant treated infants, PDA size (1.9 ± 0.8 vs 1.9 ± 0.8 mm, respectively, P ¼ 0.901), mean blood flow velocity (1.0±0.8 vs 0.8 ± 0.5 m s -1 , respectively, P ¼ 0.883) and calculated flow (123 ± 119 vs 137 ± 107 cc min -1 , respectively, P ¼ 0.654) were similar, and did not change significantly from baseline with surfactant administration. Similarly, RVP (35 ± 12 vs 39±13 mm Hg, P ¼ 0.555) and RVP/SAP (71±24 vs 87±14%, P ¼ 0.352) in infants treated with poractant alfa and beractant were similar, and did not change significantly with surfactant administration. Thus, in the first days of life, neither surfactant appeared to have a significant direct affect on PDA patency or on the hemodynamic effect.
Discussion
The primary finding of this study is a description of the interaction between pulmonary function and PDA hemodynamics in very premature infants with RDS, treated with poractant alfa or beractant. This is a highly selected population of very premature infants with RDS requiring mechanical ventilation; infants that were at greatest risk for common morbidities of prematurity, including hemodynamically significant PDAs. While early echocardiograms at 2 to 7 days showed a similar frequency and size of PDAs in each group, fewer infants in the poractant alfa group were treated with indomethacin or surgical ligation than in the beractant group. Medical treatment of significant PDAs tended to be earlier in the poractant alfa treated infants, corresponding to a significantly lower RVP/Sys Art BP ratio than in the beractant group. These differences were associated with a more rapid and sustained improvement in respiratory function in the poractant alfa group, allowing more elective extubations at 48 and 72 h than in the beractant group. 6 We did not demonstrate a direct surfactant effect on PDA closure or PDA hemodynamics by echocardiographic evaluation following the second dose of poractant alfa or beractant. Since PDAs tended to be treated earlier in the poractant alpha group, yet there were more PDAs treated in the beractant group, it is unlikely that early treatment of PDAs that would have close spontaneously, accounted for the lower number of PDAs treated in the poractant alfa group. Furthermore, since the number and size of PDAs seen in the echocardiograms performed at 2 to 7 days were similar in the two groups, there appears to be other factors responsible for persistence of the PDAs in the beractant than in the poractant alfa group. We believe the difference in pulmonary function or need for persistent mechanical ventilation was directly or indirectly responsible for the difference in PDAs treated in the two groups.
We speculate that the improved pulmonary status in the poractant alfa group allowed more PDA closures than in the beractant group. Either less aggressive clinical management of PDAs in infants on CPAP or nasal cannula oxygen or improved pulmonary status facilitating PDA closure may explain the differences in PDAs treated in the two groups. Although we performed serial echocardiograms to monitor PDA closure and remain as objective as possible, PDA treatment was not blinded to the open label surfactant administered. We believe that our study is the most comprehensive, prospective echocardiographical evaluation available of PDAs, comparing the interaction between the effects of two different surfactant preparations and PDA hemodynamics in very premature infants with RDS. We included an evaluation of the effects of surfactant in the first week of life and a limited evaluation of the acute effect (first hour after surfactant administration) for two surfactant preparations. To our knowledge, there is no similar study. Our data support the hypothesis that therapies that induce a sustained improvement in respiratory function and require less mechanical ventilation may Patent ductus arteriosus hemodynamics A Fujii et al be associated with a lower incidence of hemodynamically significant PDAs. The need to evaluate responses to different surfactant preparations and timing of the evaluations is important in the evaluations of hemodynamic responses to surfactant preparations. For example, the cerebral blood flow response to a prophylactic first surfactant dose of beractant or poractant alfa decreased cerebral blood flow whereas cerebral blood flow increased following a second dose of beractant and did not change with the second dose of poractant alfa. 8, 9 We speculated that the unifying hypothesis was that the cerebral blood flow responses mirrored the acute increases or decreases in pCO 2 associated with surfactant administration. 8, 9 Differences in surfactant preparations, volume and timing of administration probably explain the widely different cerebral blood flow responses to surfactant. Previous studies reported that cerebral blood flow decreased, 10-13 increased 9,14 -18 and remained unchanged [19] [20] [21] [22] [23] [24] following various surfactant preparations, administered under varying conditions. Thus, as with the cerebral circulation, we believe that the differential pulmonary effects of beractant and poractant alfa may be responsible for indirect effects on PDAs and PDA hemodynamics.
The rapid onset of action of poractant alfa in improving lung compliance and oxygenation, compared with beractant, reduced the need for mechanical ventilation in premature infants with RDS. 6, 25 Improved oxygenation may increase PDA closure rates. 26 Higher levels of positive pressure mechanical ventilation in the beractant group, compared with the poractant alfa group, may have stimulated a chronic inflammatory response that has been associated with development of chronic lung disease and PDAs through activation of the inflammatory cascade and prostaglandin synthesis. 27, 28 Our findings are analogous to improved pulmonary status and lesser need for PDA treatment in infants treated with early caffeine treatment, 29 where no direct effect of caffeine on periductal ductal smooth muscle constriction was demonstrable. 30 The primary weaknesses of this study were the small sample size, open label design and high rate of PDAs in the beractant group. This is a highly selected population of very premature infants who were mechanically ventilated for RDS, infants with the greatest risk of developing the morbidities of prematurity, including PDAs and chronic lung disease. Our observation extends the findings of Malloy et al.
5 who also found a lower incidence of PDAs in infants treated with poractant alfa, compared with beractanttreated infants.
In conclusion, this is a comprehensive, prospective, hemodynamic study examining the interaction of two animalderived surfactant preparations on PDAs and PDA hemodynamics in very premature infants with RDS. There were fewer significant PDAs requiring medical or surgical treatment in infants treated with poractant alfa, than in those treated with beractant. The differences in PDA treatment and hemodynamics were associated with a differential effect on respiratory support. The infants treated with poractant alfa required less mechanical ventilatory support than those treated with beractant. Neither poractant alfa nor beractant had direct hemodynamic effects on PDAs or PDA hemodynamics following the second surfactant dose in infants with severe RDS. We speculate that the difference in PDAs was due to an indirect differential effect of these surfactant preparations on pulmonary function and associated PDA closure. Further studies will be needed to confirm our observation and clarify this relationship.
Conflict of interest Dr Fujii was supported by an unrestricted research grant from Dey LP, Napa, CA and Chiesi Farmaceutici Spa, Parma, Italy. The remaining authors declare no conflict of interest.
The funders had no involvement in study design, in data collection, analysis/interpretation of the data, in the writing of the paper or in the decision to submit the paper for publication.
